DGAT1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for DGAT1 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
19 Direct drug records from Target & Disease MCP | 7 Development records in target context | 20 Disease associations captured | 42 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
Biology signal
DGAT1 catalyzes the terminal committed step in triacylglycerol synthesis using diacylglycerol and fatty acyl-CoA. Target & Disease MCP highlights its importance in intestinal dietary-fat absorption, hepatic fat storage, VLDL assembly, and retinoid homeostasis in skin.
Validation evidence
The clinical dataset is modest but informative. Target & Disease MCP returned 19 drug records and 7 development records, while Clinical Trials MCP returned 42 trial records, with examples in healthy-volunteer, ADME, and drug-drug interaction settings.
Competition and differentiation
DGAT1 has clear mechanistic relevance, but historical tolerability and GI-related issues make translation difficult. Differentiation would need tissue targeting, controlled exposure, or a very specific metabolic indication where the benefit-risk tradeoff is acceptable.
IP and partnering view
IP work should scrutinize small-molecule chemistry, gut-restricted strategies, combination approaches, and safety-management claims. Because the clinical path is narrower than for broader lipid targets, the strategic thesis must be very precise.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 42 registered trial records connected to DGAT1. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| PRADIGASTAT Phase 1 study in healthy subjects | Phase 1 | Terminated |
| ADME study of radiolabeled PF-06865571 in healthy adult males | Phase 1 | Completed |
| Drug-drug interaction study between PF-06882961 and PF-06865571 | Phase 1 | Completed |
R&D Strategy Recommendation
DGAT1 is a selective-opportunity target rather than a broad cardiovascular platform. Advance only if the program can solve tolerability and exposure questions; otherwise, use MCP monitoring to watch for improved gut-restricted or indication-specific strategies.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
